Chief Executive Officer - Biotechnology - CRO - Ref.: JVM180820MI

Our client is seeking a CEO for a services platform company in antibody research that has been set up with the support of the University of Aix Marseille; the role will be based there. It can best be described as a platform within the university that provides essential R&D services related to antibody therapeutics to third parties.

The incoming CEO will be responsible for taking the lead and executing the restructuring current operation into a new standalone business. The successful restructuring requires the transfer of most of the employment contracts from AMU to the new company, a process that includes a potential reorganization of the existing reporting structure; the cancellation and establishment/renegotiation of all existing contracts with its customers; renegotiating the costs such as the leasing cost of the premises. The restructuring also requires a financial investment of circa 3M€, a process that has started but will be taken over by the CEO.

This is an outstanding opportunity to lead an innovative organization within a highly acclaimed area of antibody therapeutics. The role will suit a driven, creative, entrepreneurial and even disruptive thinker; a proven Chief Executive Officer who has a track record of successfully building commercial value, preferentially in the services business. The role holder must be fluent in written and spoken French and English.

Application Instructions: 
Application Closing Date: 
31 December 2020